Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2001-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Giving more than one drug and giving the drugs in different ways
may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens
of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or
metastatic non-small cell lung cancer.
Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Completed
Alliance for Clinical Trials in Oncology
Phase 2
2001-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Giving more than one drug and giving the drugs in different ways
may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens
of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or
metastatic non-small cell lung cancer.
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Completed
Eli Lilly and Company
Phase 1
1969-12-31
This is a non-randomized, phase 1, study with the primary objective of determining the
toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10
minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in
lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.